Morgan Stanley Call 250 COR 20.09.../ DE000ME4MNF8 /
| 2024-05-29 8:31:08 PM | Chg.+0.21 | Bid10:00:32 PM | Ask10:00:32 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.51EUR | +16.15% | - Bid Size: - |
- Ask Size: - |
Cencora Inc | 250.00 USD | 2024-09-20 | Call |
GlobeNewswire
05-28
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizuma...
GlobeNewswire
05-15
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...
GlobeNewswire
05-13
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
05-09
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...
GlobeNewswire
04-29
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...
GlobeNewswire
04-17
2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners
GlobeNewswire
03-22
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...
GlobeNewswire
03-18
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
GlobeNewswire
02-14
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire
01-23
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...
GlobeNewswire
2023-12-22
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...
GlobeNewswire
2023-12-19
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...
GlobeNewswire
2023-11-27
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path For...
GlobeNewswire
2023-11-14
Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior V...
